Navigation Links
Study identifies new approach to improving treatment for MS and other conditions
Date:5/17/2013

(SACRAMENTO, Calif.) Working with lab mice models of multiple sclerosis (MS), UC Davis scientists have detected a novel molecular target for the design of drugs that could be safer and more effective than current FDA-approved medications against MS.

The findings of the research study, published online today in the journal EMBO Molecular Medicine could have therapeutic applications for MS as well as cerebral palsy and leukodystrophies, all disorders associated with loss of white matter, which is the brain tissue that carries information between nerve cells in the brain and the spinal cord.

The target, a protein referred to as mitochondrial translocator protein (TSPO), had been previously identified but not linked to MS, an autoimmune disease that strips the protective fatty coating off nerve fibers of the brain and spinal cord. The mitrochronical TSPO is located on the outer surface of mitochondria, cellular structures that supply energy to the cells. Damage to the fatty coating, or myelin, slows the transmission of the nerve signals that enable body movement as well as sensory and cognitive functioning.

The scientists identified mitochondrial TSPO as a potential therapeutic target when mice that had symptoms of MS improved after being treated with the anti-anxiety drug etifoxine, which interacts with mitochondrial TSPO. When etifoxine, a drug clinically available in Europe, was administered to the MS mice before they had clinical signs of disease, the severity of the disease was reduced when compared to the untreated lab animals. When treated at the peak of disease severity, the animals' MS symptoms improved.

"Etifoxine has a novel protective effect against the loss of the sheath that insulates the nerve fibers that transmit the signals from brain cells," said Wenbin Deng, principal investigator of the study and associate professor of biochemistry and molecular medicine at UC Davis.

"Our discovery of etifoxine's effects on an MS animal model suggests that mitochondrial TSPO represents a potential therapeutic target for MS drug development," said Deng.

"Drugs designed to more precisely bind to mitochondrial TSPO may help repair the myelin sheath of MS patients and thereby even help restore the transmission of signals in the central nervous system that enable normal motor, sensory and cognitive functions," he said.

Deng added that better treatments for MS and other demyelinating diseases are needed, especially since current FDA-approved therapies do not repair the damage of immune attacks on the myelin sheath.

The UC Davis research team hopes to further investigate the therapeutic applications of mitochondrial TSPO in drug development for MS and other autoimmune diseases. To identify more efficacious and safer drug candidates, they plan to pursue research grants that will enable them to test a variety of pharmacological compounds that bind to mitochondrial TSPO and other molecular targets in experimental models of MS and other myelin diseases.

The journal paper is entitled, "A TSPO ligand is protective in a mouse model of multiple sclerosis."


'/>"/>

Contact: Charles Casey
charles.casey@ucdmc.ucdavis.edu
916-734-9048
University of California - Davis Health System
Source:Eurekalert

Related medicine news :

1. Study: Peer-referral programs can increase HIV-testing in emergency departments
2. New study pinpoints biochemical mechanism underlying fibrosis following glaucoma surgery
3. Study: Patient openness to research can depend on race and sex of study personnel
4. The Institute of Regenerative & Molecular Orthopedics Applauds Newly Released Study on Platelet-Rich Plasma
5. Study suggests new role for ECMO in treating patients with cardiac arrest and profound shock
6. Bel Marra Health Reports on a New Study Revealing a Natural Remedy for Hypertension, Insomnia, and Aging
7. Study Finds Overweight Young Males Have a Greater Risk of Not Surviving Until Age 55, Making Weight Loss Supplements Like Prescopodene Helpful With Increasing Longevity
8. New Study Reveals that Fitness Levels May Affect Attention Span, Making Weight Loss, Such as With Prescopodene, Helpful With Promoting Concentration
9. New study recommends using active videogaming (exergaming) to improve childrens health
10. Study: Brain makes call on which ear is used for cell phone
11. 2013 Is the Year of Mobility in Government: Study Shows Media Landscape Shifting in Government Sector
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... , ... A new collaboration will give more researchers access to the largest ... analytics leader SAS will provide researchers worldwide with data management and analytics tools to ... , The DCRI and SAS share the goal of greater transparency and openness ...
(Date:5/4/2016)... ... May 04, 2016 , ... Slepkow Slepkow & ... one of the top website design companies to create a state of the ... to the law firm's main practice areas. These practice areas include: real estate, ...
(Date:5/4/2016)... ... May 04, 2016 , ... Francesca Loparco, Co-Founder of Queen City Dream Cars, ... same-day LASIK procedure at Christenbury Eye Center. The entrepreneur struggled with her ... surgery the same day as her in-office consultation and eye exam. Francesca’s eyesight was ...
(Date:5/4/2016)... ... 2016 , ... Advanced Spine & Sport Medical Rehabilitation Center, which is renowned ... a free seminar on stem cell injections. The seminar is scheduled for Wednesday, May ... Telephone Road, Suite 110, Ventura, CA. There are only 10 seats available. , ...
(Date:5/4/2016)... Lenexa, KS (PRWEB) , ... May 04, 2016 ... ... Transtem™ Patient 2016, a powerful cellular therapy software application that helps ... life-saving treatments to patients. , Since Transtem’s initial launch, Mediware has continued to ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... , May 4, 2016 ... of the  "Global Multiple Myeloma Market and ... their offering.       (Logo: ... Market and Competitive Landscape Highlights 2016, provides ... Multiple Myeloma epidemiology, Multiple Myeloma market valuations ...
(Date:5/4/2016)... , May 4, 2016 ... of the  "Global Acute lymphocytic Leukemia Market ... to their offering.       (Logo: ... Acute Lymphocytic Leukemia Market and Competitive Landscape ... Lymphocytic Leukemia pipeline products, Acute Lymphocytic Leukemia ...
(Date:5/3/2016)... , May 3, 2016  Axiogenesis has acquired a major investment from Sino-German High-Tech Fund to further expand product ... Photo - http://photos.prnewswire.com/prnh/20160503/362921 ... ... ... ...
Breaking Medicine Technology: